1. Hyaluronan synthesis inhibition impairs antigen presentation and delays transplantation rejection.
- Author
-
Marshall PL, Nagy N, Kaber G, Barlow GL, Ramesh A, Xie BJ, Linde MH, Haddock NL, Lester CA, Tran QL, de Vries CR, Hargil A, Malkovskiy AV, Gurevich I, Martinez HA, Kuipers HF, Yadava K, Zhang X, Evanko SP, Gebe JA, Wang X, Vernon RB, de la Motte C, Wight TN, Engleman EG, Krams SM, Meyer EH, and Bollyky PL
- Subjects
- Animals, Antigen Presentation drug effects, Cell Proliferation drug effects, Cells, Cultured, Dendritic Cells drug effects, Dendritic Cells metabolism, Disease Models, Animal, Graft Rejection immunology, Heart Transplantation adverse effects, Humans, Hymecromone pharmacology, Leukocytes cytology, Leukocytes drug effects, Leukocytes immunology, Mice, Pancreas Transplantation adverse effects, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory metabolism, Transplantation, Homologous, Dendritic Cells cytology, Graft Rejection prevention & control, Hyaluronic Acid biosynthesis, Hymecromone administration & dosage, T-Lymphocytes, Regulatory cytology
- Abstract
A coat of pericellular hyaluronan surrounds mature dendritic cells (DC) and contributes to cell-cell interactions. We asked whether 4-methylumbelliferone (4MU), an oral inhibitor of HA synthesis, could inhibit antigen presentation. We find that 4MU treatment reduces pericellular hyaluronan, destabilizes interactions between DC and T-cells, and prevents T-cell proliferation in vitro and in vivo. These effects were observed only when 4MU was added prior to initial antigen presentation but not later, consistent with 4MU-mediated inhibition of de novo antigenic responses. Building on these findings, we find that 4MU delays rejection of allogeneic pancreatic islet transplant and allogeneic cardiac transplants in mice and suppresses allogeneic T-cell activation in human mixed lymphocyte reactions. We conclude that 4MU, an approved drug, may have benefit as an adjunctive agent to delay transplantation rejection., Competing Interests: Declaration of Competing Interest The authors have no competing financial interests. N.N., P.L.M., and P.L.B. are listed as inventors of the patent (PCT/US2019/019310) filed by the Board of Trustees of the Leland Stanford Junior University., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF